Form 10-Q Dipexium Pharmaceuticals For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dipexium Pharmaceuticals (DPRX) Misses Q2 EPS by 4c
August 13, 2015 9:03 AM EDTDipexium Pharmaceuticals (NASDAQ: DPRX) reported Q2 EPS of ($0.47), $0.04 worse than the analyst estimate of ($0.43).
For earnings history and earnings-related data on Dipexium Pharmaceuticals (DPRX) click here.
... More